EVICEL

This brand name is authorized in Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Ireland, Lithuania, Poland, Singapore, UK.

Active ingredients

The drug EVICEL contains a combination of these active pharmaceutical ingredients (APIs):

1	Human clottable protein UNII N94833051K - FIBRINOGEN HUMAN
	Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (F XIIIa) and calcium ions is converted into a stable and elastic three-dimensional fibrin haemostatic clot. The administration of human fibrinogen concentrate provides an increase in plasma fibrinogen level and can temporarily correct the coagulation defect of patients with fibrinogen deficiency.
	Read more about Human fibrinogen
2	Thrombin UNII 6K15ABL77G - HUMAN THROMBIN
	Read more about Thrombin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BC	Local hemostatics	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics
Discover more medicines within B02BC
B02BC30	Combinations	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BC Local hemostatics
Discover more medicines within B02BC30

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	537400201136312, 537400202132310, 537400203139319
CA	Health Products and Food Branch	02348497
EE	Ravimiamet	1384264, 1391813, 1391824
FI	Lääkealan turvallisuus- ja kehittämiskeskus	047911, 412047
FR	Base de données publique des médicaments	63665312
GB	Medicines & Healthcare Products Regulatory Agency	182783, 182795
LT	Valstybinė vaistų kontrolės tarnyba	1036589, 1036590, 1036591
PL	Rejestru Produktów Leczniczych	100227539
SG	Health Sciences Authority	13921P